Rabies: New prophylactic and therapeutic avenues

Rabies is still responsible for approximately 60,000 human deaths per year mostly in Asia and Africa and affects especially underserved people. Prophylactic measures have significantly improved. They are now composed of the vaccine allied to purified human or equine rabies immunoglobulins. However, these immunoglobulins are expensive and not easy to reach in developing settings. Researchers have visualized one of the most potent and most broadly neutralizing human monoclonal antibody in interaction with the rabies glycoprotein.